CoChat

Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement

Open access
Guckenberger, Matthias, Belka, Claus, Bezjak, Andrea, Bradley, Jeffrey, Daly, Megan E., DeRuysscher, Dirk, Dziadziuszko, Rafal, Faivre-Finn, Corinne, Flentje, Michael, Gore, Elizabeth, Higgins, Kristin A., Iyengar, Puneeth, Kavanagh, Brian D, Kumar, Sameera, Le Pechoux, Cecile, Lievens, Yolande, Lindberg, Karin, McDonald, Fiona, Ramella, Sara, Rengan, Ramesh, Ricardi, Umberto, Rimner, Andreas, Rodrigues, George B., Schild, Steven E., Senan, Suresh, Simone II, Charles B., Slotman, Ben J., Stuschke, Martin, Videtic, Greg, Widder, Joachim, Yom, Sue S., Palma, David · 2020 · Radiotherapy and Oncology
Cited by 225

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radiotherapy established this practice recommendation pertaining to whether and how to adapt radiotherapy for lung cancer in the COVID-19 pandemic. METHODS: For this ESTRO & ASTRO endorsed project, 32 experts in lung cancer radiotherapy contributed to a modified Delphi consensus process. We assessed potential adaptations of radiotherapy in two pandemic scenarios. The first, an early pandemic scenario of risk mitigation, is characterized by an altered risk-benefit ratio of radiotherapy for lung cancer patients due to their increased susceptibility for severe COVID-19 infection, and minimization of patient travelling and exposure of radiotherapy staff. The second, a later pandemic scenario, is characterized by reduced radiotherapy resources requiring patient triage. Six common lung cancer cases were assessed for both scenarios: peripherally located stage I NSCLC, locally advanced NSCLC, postoperative radiotherapy after resection of pN2 NSCLC, thoracic radiotherapy and prophylactic cranial irradiation for limited stage SCLC and palliative thoracic radiotherapy for stage IV NSCLC. RESULTS: In a risk-mitigation pandemic scenario, efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. In that same scenario, postponement or interruption of radiotherapy treatment of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection. In a severe pandemic scenario characterized by reduced resources, if patients must be triaged, important factors for triage include potential for cure, relative benefit of radiation, life expectancy, and performance status. Case-specific consensus recommendations regarding multimodality treatment strategies and fractionation of radiotherapy are provided. CONCLUSION: This joint ESTRO-ASTRO practice recommendation established pragmatic and balanced consensus recommendations in common clinical scenarios of radiotherapy for lung cancer in order to address the challenges of the COVID-19 pandemic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.radonc.2020.04.001

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 225

Metadata

Authors
Guckenberger, M., Belka, C., Bezjak, A., Bradley, J., Daly, M. E., DeRuysscher, D., Dziadziuszko, R., Faivre-Finn, C., Flentje, M., Gore, E., Higgins, K. A., Iyengar, P., Kavanagh, B. D., Kumar, S., Le Pechoux, C., Lievens, Y., Lindberg, K., McDonald, F., Ramella, S., Rengan, R., Ricardi, U., Rimner, A., Rodrigues, G. B., Schild, S. E., Senan, S., Simone II, C. B., Slotman, B. J., Stuschke, M., Videtic, G., Widder, J., Yom, S. S., & Palma, D.
Venue
Radiotherapy and Oncology
Publisher
Elsevier BV
Published
2020-05
Volume
146
Issue
4
Pages
223-229
ISSN
0167-8140 (ISSN-L)
OpenAlex
W3014909787
Cited by
225
References
4
FWCI
15.88
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.